巩固英股“第一大权重股”地位，医药巨头阿斯利康股价创新高

Core Viewpoint - AstraZeneca's stock price reached a historic high of £134.6, driven by strong Q3 earnings and a favorable U.S. drug pricing agreement, boosting market confidence and contributing to the rise of the FTSE 100 index [1][3][7]. Group 1: Stock Performance - On November 11, AstraZeneca's stock price increased by 2.5% to £134.6, marking a historic high and solidifying its position as the largest weight in the FTSE 100 index [3][5]. - The company's market capitalization approached £210 billion (approximately $282 billion), reinforcing its status as the leading stock in the UK market [3]. Group 2: Financial Performance - AstraZeneca reported a Q3 revenue growth of 11% year-over-year and a core earnings per share increase of 15%, with all business segments and key regional markets showing robust growth [7]. - The strong performance was primarily driven by sustained demand for innovative drugs [7]. Group 3: Market Factors - The recent U.S. drug pricing agreement reached in October alleviated market concerns regarding U.S. pharmaceutical policy uncertainty, providing additional support for AstraZeneca's stock price [7]. - The U.S. market, contributing over 40% of AstraZeneca's total sales, plays a significant role in influencing the company's stock performance [7].